NEWS

  • January 29, 2018

    ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results

    ZZ Biotech Announces Preliminary Phase 2 Stroke Trial Results with 3K3A-APC Houston, TX, USA, January 29, 2018 / B3C newswire / -- ZZ Biotech today announced that preliminary results of RHAPSODY, the...

    Read More
  • November 21, 2017

    480 Biomedical’s Novel Technology Featured in Nature Materials

    480 Biomedical develops new technology which imparts metal-like strength on bioresorbable polymers WATERTOWN, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- 480 Biomedical, a clinical-stage life science c...

    Read More
  • October 10, 2017

    Boston Scientific Announces Agreement to Acquire Apama Medical

    Acquisition to Strengthen Company's Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial Fibrillation Oct 2, 2017 MARL...

    Read More
  • May 24, 2017

    New Options in Wireless Remote Patient Monitoring

    Interview with Michael Mazzini, MD Author(s): Interview by Jodie Elrod Issue Number: Volume 17 - Issue 5 - May 2017 Dr. Michael Mazzini is with North Suburban Cardiology Associates in Stoneham, M...

    Read More
  • May 15, 2017

    Biogen Acquires Remedy Pharmaceuticals’ CIRARA™ for Large Hemispheric Stroke

    Phase 3-ready program complements Biogen’s ongoing development efforts in stroke Biogen will pay a $120 million upfront payment plus potential milestone and royalty payments May 15, 20...

    Read More
  • April 28, 2017

    Simple New Test Might Be a Better Way to Diagnose Gestational Diabetes

    Link to publication below: Mellitus Study Mentioned in "What to Expect" Magazine...

    Read More
  • April 27, 2017

    Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening

    Mellitus Reports Publication of Investigator-Initiated Study Supporting Glycated CD59 as a Novel Alternative for Gestational Diabetes Screening -A single blood test to measure GCD59 at week 24-28 of...

    Read More
  • April 4, 2017

    InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer

    InfoBionic Names Industry Veteran Stuart Long Chief Executive Officer Signals next phase of expansion with cardiologists and electrophysiologists to improve the quality of patient care, reduce costs,...

    Read More
  • March 6, 2017

    Herantis Pharma’s clinical study with Lymfactin advances to high dose level

    Herantis Pharma’s clinical study with Lymfactin advances to high dose level Herantis Pharma PlcCompany release 6 March 2017 at 10:00 am Herantis Pharma Plc’s (“Herantis”) clinical study with...

    Read More
  • February 13, 2017

    miRagen Therapeutics Completes merger with Signal Genetics and Concurrent $40.7M Equity Financing

    BOULDER, CO – February 13, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, to...

    Read More